Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|February 1, 2003
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-02-01-2003
- Volume 15
- Issue 2
It's my Constitution, Doctor
Author(s)Albedo
Brussels report
Advertisement
As the deadline approaches for the Euroepan Union to adopt s dozen new member states, the pharmaceutical industry has expressed its concern that an expanded EU would no longer be able to effectively legislate health care policy. A revised proposal from the EC concerning medicine rules has been prepared, but final agreement on all points still seems a long way off.
This article is currently available in printed form only.
To ensure access to all articles from every issue of Pharmaceutical Technology Europe
Articles in this issue
over 23 years ago
Liposomes, Part II: Drug delivery systemsover 23 years ago
Containment Levels and Facility Designover 23 years ago
Manufacturing Capability Key to Global Health AdvancesAdvertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
2
Ask the Expert: Post-Approval Changes
3
PharmTech’s Weekly Roundup—September 25, 2026
4
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
5